Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. insiders are currently net buyers of FHTX stock, showing bullish sentiment over the past 90 days. Executives have purchased $24.9M while selling $3.4M, resulting in a positive net flow of $21.5M. This buying activity represents 88% of total transaction volume.

Foghorn Therapeutics Inc. has 23 active insiders who have filed SEC Form 4 transactions in the past 90 days. Noubar Afeyan (Executive) leads with 2 transactions totaling $20.0M. Samuel Agresta (Executive) follows with 2 transactions worth $3.7M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Foghorn Therapeutics Inc.'s current score of 88/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $24.9M in purchases versus $3.4M in sales.

The most recent insider transaction occurred on Sep 23, 2024, when Costa Carlos (Executive) disposed of 857 shares at $0.00 per share for $0. This was executed under a 10b5-1 trading plan.

Based on SEC Form 4 filings from the past 90 days, FHTX insider trading sentiment is currently bullish with an Alignment Score of 88/100. The net insider flow of $21.5M reflects accumulation, with 88% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Foghorn Therapeutics Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At FHTX, we track all Form 4 filings—currently showing 71 transactions from 23 insiders over 90 days.

A 10b5-1 plan allows Foghorn Therapeutics Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At FHTX, approximately 32% of recent transactions are 10b5-1 trades. The remaining 68% are discretionary trades, which may carry more informational value.

You can monitor Foghorn Therapeutics Inc. (FHTX) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 23 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Foghorn Therapeutics Inc.'s current score of 88/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $24.9M in purchases versus $3.4M in sales over 90 days, resulting in a net flow of $21.5M.

SEC Form 4 filings are mandatory reports that Foghorn Therapeutics Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At FHTX, the most common type is "A" with 16 occurrences. The most recent Form 4 was filed on Sep 23, 2024 by Costa Carlos.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Foghorn Therapeutics Inc., approximately 32% of recent transactions are executed under 10b5-1 plans, while 68% appear to be discretionary trades. This mix provides a balanced picture—some planned, others reflecting real-time decisions.